Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Astellas Pharma publishes third-quarter results

Astellas Pharma publishes third-quarter results

4th February 2008

Astellas Pharma has published its financial results for the first three quarters of its 2007 fiscal year which will end on March 31st 2008.

Consolidated net sales generated for the nine months reached 765.2 billion yen (3.6 billion pounds), an increase of 8.9 per cent on the figures for the first nine months of the 2006 fiscal year.

Operating income increased 63.4 per cent on the previous year’s figures to 245.4 billion yen, while net income rose 51.7 per cent to 161.2 billion yen.

Earnings per share rose from 194.8 yen for the first three quarters of 2006 to 316.1 yen in the first three quarters of the current fiscal year.

Following the publication of these results, Astellas Pharma has revised its consolidated business forecasts for the 2007 fiscal year, now forecasting net sales of 971 billion yen, a 5.5 increase on the full-year figure for 2006.

“In Europe, sales increased 18.2 per cent to 187.2 billion yen,” the company said.

“Sales of Prograf and Vesicare increased in European market and bulk sales to and royalty revenue from licensees of Hamal increased due to the robust sales in the US market by the licensee.”

The company added that sales of Eligard, its treatment for advanced prostate cancer, also expanded during the period.

In November 2007, Astellas Pharma announced that its US holding subsidiary had signed an agreement to purchase Agensys for the total sum of $387 million (187.96 million pounds).

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.